Literature DB >> 20385270

Radiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children's Research Hospital experience.

Jared R Robbins1, Matthew J Krasin, Atmaram S Pai Panandiker, Amy Watkins, Jianrong Wu, Victor M Santana, Wayne L Furman, Andrew M Davidoff, Lisa M McGregor.   

Abstract

PURPOSE: The purpose of the study was to compare outcomes of pediatric patients with high-risk metastatic neuroblastoma who received radiotherapy (RT) with those of patients who did not. PATIENTS AND METHODS: We reviewed the records of 63 patients with newly diagnosed metastatic neuroblastoma treated at our institution (1989-2001) to investigate their characteristics at presentation, dose and field of RT, treatment response, and failure patterns.
RESULTS: Seventeen patients received RT, and 46 did not. In the RT group, a greater percentage of patients had residual disease before consolidation than did those in the no-RT group (88.2% vs 69.6%, P = .008). Gross total resection was achieved less often in the RT group (65% vs 89%, P = .055), but the 5-year cumulative incidences of local failure were similar (35.3% +/- 12.4% vs 32.6% +/- 7.1%). Although there was no difference in 5-year event-free survival, overall survival was better in the no-RT group (47.8% +/- 7.2% vs 23.5% +/- 9.2%, P = .026).
CONCLUSION: The addition of RT to the therapy of a group of patients with more residual locoregional disease appeared to improve the local failure rate to approximately that of patients with less residual disease. Radiotherapy may provide even greater benefit to those with less residual disease before consolidation. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20385270      PMCID: PMC2897834          DOI: 10.1016/j.jpedsurg.2009.11.003

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  33 in total

1.  Local control with multimodality therapy for stage 4 neuroblastoma.

Authors:  S L Wolden; S V Gollamudi; B H Kushner; M LaQuaglia; K Kramer; N Rosen; S Abramson; N V Cheung
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-03-01       Impact factor: 7.038

2.  The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease: the St. Jude Children's Research Hospital Experience.

Authors:  Lisa M McGregor; Bhaskar N Rao; Andrew M Davidoff; Catherine A Billups; Suradej Hongeng; Victor M Santana; D Ashley Hill; Christine Fuller; Wayne L Furman
Journal:  Cancer       Date:  2005-12-15       Impact factor: 6.860

3.  Neuroblastoma with symptomatic spinal cord compression at diagnosis: treatment and results with 76 cases.

Authors:  C Pianca; P Pistamiglio; E Veneselli; E Viscardi; A Pession; P Alvisi; M Carli; A Donfrancesco; F Casale; M G Giuliano; L C di Montezemolo; A Di Cataldo; M Lo Curto; S Bagnulo; R F Schumacher; A Tamburini; A Garaventa; L Clemente; P Bruzzi
Journal:  J Clin Oncol       Date:  2001-01-01       Impact factor: 44.544

4.  Impact of TBI on late effects in children treated by megatherapy for Stage IV neuroblastoma. A study of the French Society of Pediatric oncology.

Authors:  Isabelle Flandin; Olivier Hartmann; Jean Michon; Ross Pinkerton; Carole Coze; Jean Louis Stephan; Bernard Fourquet; Dominique Valteau-Couanet; Christophe Bergeron; Thierry Philip; Christian Carrie
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-01-19       Impact factor: 7.038

5.  Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study.

Authors:  C S Alvarado; W B London; A T Look; G M Brodeur; D H Altmiller; P S Thorner; V V Joshi; S T Rowe; M B Nash; E I Smith; R P Castleberry; S L Cohn
Journal:  J Pediatr Hematol Oncol       Date:  2000 May-Jun       Impact factor: 1.289

6.  Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.

Authors:  Katherine K Matthay; C Patrick Reynolds; Robert C Seeger; Hiroyuki Shimada; E Stanton Adkins; Daphne Haas-Kogan; Robert B Gerbing; Wendy B London; Judith G Villablanca
Journal:  J Clin Oncol       Date:  2009-01-26       Impact factor: 44.544

7.  Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.

Authors:  Katherine K Matthay; Gregory Yanik; Julia Messina; Alekist Quach; John Huberty; Su-Chun Cheng; Janet Veatch; Robert Goldsby; Patricia Brophy; Leslie S Kersun; Randall A Hawkins; John M Maris
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

8.  A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.

Authors:  Kaci L Osenga; Jacquelyn A Hank; Mark R Albertini; Jacek Gan; Adam G Sternberg; Jens Eickhoff; Robert C Seeger; Katherine K Matthay; C Patrick Reynolds; Clare Twist; Mark Krailo; Peter C Adamson; Ralph A Reisfeld; Stephen D Gillies; Paul M Sondel
Journal:  Clin Cancer Res       Date:  2006-03-15       Impact factor: 12.531

9.  Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.

Authors:  Paxton V Dickson; John B Hamner; Thomas L Sims; Charles H Fraga; Catherine Y C Ng; Surender Rajasekeran; Nikolaus L Hagedorn; M Beth McCarville; Clinton F Stewart; Andrew M Davidoff
Journal:  Clin Cancer Res       Date:  2007-07-01       Impact factor: 12.531

10.  Activating mutations in ALK provide a therapeutic target in neuroblastoma.

Authors:  Rani E George; Takaomi Sanda; Megan Hanna; Stefan Fröhling; William Luther; Jianming Zhang; Yebin Ahn; Wenjun Zhou; Wendy B London; Patrick McGrady; Liquan Xue; Sergey Zozulya; Vlad E Gregor; Thomas R Webb; Nathanael S Gray; D Gary Gilliland; Lisa Diller; Heidi Greulich; Stephan W Morris; Matthew Meyerson; A Thomas Look
Journal:  Nature       Date:  2008-10-16       Impact factor: 49.962

View more
  11 in total

1.  Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma.

Authors:  Dana L Casey; Brian H Kushner; Nai-Kong V Cheung; Shakeel Modak; Michael P LaQuaglia; Suzanne L Wolden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-05-27       Impact factor: 7.038

2.  Favorable Local Control From Consolidative Radiation Therapy in High-Risk Neuroblastoma Despite Gross Residual Disease, Positive Margins, or Nodal Involvement.

Authors:  Matthew J Ferris; Hasan Danish; Jeffrey M Switchenko; Claudia Deng; Bradley A George; Kelly C Goldsmith; Karen J Wasilewski; W Thomas Cash; Mohammad K Khan; Bree R Eaton; Natia Esiashvili
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-11-27       Impact factor: 7.038

3.  Outcomes After Radiation Therapy to Metastatic Sites in Patients With Stage 4 Neuroblastoma.

Authors:  Shravan Kandula; Roshan S Prabhu; Ronica Nanda; Jeffrey M Switchenko; Thomas Cash; Muna Qayed; Howard Katzenstein; Natia Esiashvili
Journal:  J Pediatr Hematol Oncol       Date:  2015-04       Impact factor: 1.289

4.  The importance of local control management in high-risk neuroblastoma in South Africa.

Authors:  Jaques van Heerden; Mariana Kruger; Tonya Esterhuizen; Marc Hendricks; Jennifer Geel; Ané Büchner; Gita Naidu; Jan du Plessis; Barry Vanemmenes; Ronelle Uys; G P Hadley
Journal:  Pediatr Surg Int       Date:  2020-02-28       Impact factor: 1.827

5.  Implications of Image-Defined Risk Factors and Primary-Site Response on Local Control and Radiation Treatment Delivery in the Management of High-Risk Neuroblastoma: Is There a Role for De-escalation of Adjuvant Primary-Site Radiation Therapy?

Authors:  John T Lucas; M Beth McCarville; David A Cooper; Mikhail Doubrovin; Daniel Wakefield; Teresa Santiago; Yimei Li; Xingyu Li; Matthew Krasin; Victor Santana; Wayne Furman; Andrew M Davidoff
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-11-26       Impact factor: 7.038

Review 6.  Is complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may >95 % tumour resection suffice?

Authors:  S Zwaveling; G A M Tytgat; D C van der Zee; M H W A Wijnen; H A Heij
Journal:  Pediatr Surg Int       Date:  2012-06-22       Impact factor: 1.827

7.  Local control in metastatic neuroblastoma in children over 1 year of age.

Authors:  Maria Antonietta De Ioris; Alessandro Crocoli; Benedetta Contoli; Maria Carmen Garganese; Gianluigi Natali; Paolo Tomà; Alessandro Jenkner; Renata Boldrini; Maria Debora De Pasquale; Giuseppe Maria Milano; Silvia Madafferi; Aurora Castellano; Franco Locatelli; Alessandro Inserra
Journal:  BMC Cancer       Date:  2015-02-21       Impact factor: 4.430

8.  Adult versus Pediatric Neuroblastoma: The M.D. Anderson Cancer Center Experience.

Authors:  Henry J Conter; Vancheswaran Gopalakrishnan; Vinod Ravi; Joann L Ater; Shreyaskumar Patel; Dejka M Araujo
Journal:  Sarcoma       Date:  2014-06-12

9.  Primary thoracic neuroblastoma in an adult: A rare case report.

Authors:  Yan-Bin Tan; Jin-Fan Li; Wen-Shan Li; Run-Lin Yang
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

10.  Proton Beam Therapy for Children With Neuroblastoma: Experiences From the Prospective KiProReg Registry.

Authors:  Danny Jazmati; Sarina Butzer; Barbara Hero; Dalia Ahmad Khalil; Julien Merta; Christian Bäumer; Gina Plum; Jörg Fuchs; Friederike Koerber; Theresa Steinmeier; Sarah Peters; Jerome Doyen; Theresa Thole; Matthias Schmidt; Christoph Blase; Stephan Tippelt; Angelika Eggert; Rudolf Schwarz; Thorsten Simon; Beate Timmermann
Journal:  Front Oncol       Date:  2021-01-20       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.